Anika Therapeutics, Inc. provided earnings guidance for the fiscal year 2024. For the year, the company expects revenue for fiscal year 2024 of $168 to $173 million, representing growth of 1% to 4% compared to 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.33 USD | -1.52% |
|
-2.58% | +11.78% |
05-30 | Caligan Partners Enters into a Cooperation Agreement with Anika Therapeutics | CI |
05-28 | Anika Therapeutics Approves $40 Million Share Repurchase Program | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.78% | 376M | |
+2.99% | 95.18B | |
-4.34% | 37.55B | |
-10.41% | 33.75B | |
+75.79% | 28.2B | |
-14.61% | 15.63B | |
-3.46% | 13.63B | |
-12.31% | 11.5B | |
+184.77% | 10.81B | |
-54.13% | 9.23B |
- Stock Market
- Equities
- ANIK Stock
- News Anika Therapeutics, Inc.
- Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024